486 related articles for article (PubMed ID: 22629478)
1. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
2. Antimony susceptible
Ghosh S; Verma A; Kumar D; Deep DK; Ramesh V; Salotra P; Singh R
Microbiol Spectr; 2024 Jun; 12(6):e0402623. PubMed ID: 38712926
[TBL] [Abstract][Full Text] [Related]
3. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
Mishra J; Madhubala R; Singh S
Parasitol Res; 2013 Mar; 112(3):1001-9. PubMed ID: 23242321
[TBL] [Abstract][Full Text] [Related]
4. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060
[TBL] [Abstract][Full Text] [Related]
5. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.
Kulshrestha A; Bhandari V; Mukhopadhyay R; Ramesh V; Sundar S; Maes L; Dujardin JC; Roy S; Salotra P
Parasitol Res; 2013 Feb; 112(2):825-8. PubMed ID: 23239091
[TBL] [Abstract][Full Text] [Related]
6. Advanced case of PKDL due to delayed treatment: A rare case report.
Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
[TBL] [Abstract][Full Text] [Related]
7. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
8. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
9. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Rijal S; Ostyn B; Uranw S; Rai K; Bhattarai NR; Dorlo TP; Beijnen JH; Vanaerschot M; Decuypere S; Dhakal SS; Das ML; Karki P; Singh R; Boelaert M; Dujardin JC
Clin Infect Dis; 2013 Jun; 56(11):1530-8. PubMed ID: 23425958
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.
Prajapati VK; Sharma S; Rai M; Ostyn B; Salotra P; Vanaerschot M; Dujardin JC; Sundar S
Am J Trop Med Hyg; 2013 Oct; 89(4):750-4. PubMed ID: 23980130
[TBL] [Abstract][Full Text] [Related]
11. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
[TBL] [Abstract][Full Text] [Related]
12. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
13. Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India.
Mandal S; Maharjan M; Singh S; Chatterjee M; Madhubala R
J Antimicrob Chemother; 2010 Mar; 65(3):496-507. PubMed ID: 20067981
[TBL] [Abstract][Full Text] [Related]
14. Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India.
Subba Raju BV; Gurumurthy S; Kuhls K; Bhandari V; Schnonian G; Salotra P
Parasitol Res; 2012 Oct; 111(4):1559-68. PubMed ID: 22752721
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani.
Verma A; Bhandari V; Deep DK; Sundar S; Dujardin JC; Singh R; Salotra P
Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):370-377. PubMed ID: 29035735
[TBL] [Abstract][Full Text] [Related]
16. Miltefosine Resistant Field Isolate From Indian Kala-Azar Patient Shows Similar Phenotype in Experimental Infection.
Khanra S; Sarraf NR; Das AK; Roy S; Manna M
Sci Rep; 2017 Sep; 7(1):10330. PubMed ID: 28871097
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
[TBL] [Abstract][Full Text] [Related]
18. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
19. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Ramesh V; Singh R; Avishek K; Verma A; Deep DK; Verma S; Salotra P
PLoS Negl Trop Dis; 2015; 9(10):e0004093. PubMed ID: 26492039
[TBL] [Abstract][Full Text] [Related]
20. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M
Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
